Drug Trial Radar · NCT04165317
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,068
Actual
Start
Dec 30, 2019
Primary completion
Dec 2, 2024
Study completion Dec 2, 2026
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder cancer. This study is seeking participants whose bladder cancer is still in early stages, has not spread outside of the bladder, has been removed with surgery, and is high risk (Part A) or was previously treated with BCG (Bacillus Calmette Guerin), a standard treatment for bladder cancer (Part B). In Part A (enrollment closed), each participant was assigned to one of three study treatment groups. * One group is given sasanlimab and BCG at the study clinic. * The second group is given sasanlimab and BCG at the study clinic. This group will receive BCG for the first six weeks only. * The third group is given BCG only and will not receive sasanlimab. In Part B of the study, each new participant will be assigned to a study treatment group based on the type of their bladder tumor. \- Both groups will be given sasanlimab at the study clinic. On August 31, 2022, the Sponsor announced the discontinuation of enrollment to Part B. The decision to discontinue enrollment to Part B was not made for safety reasons.
Conditions
- Non-muscle Invasive Bladder Cancer
Interventions
PF-06801591Drug
A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.
Bacillus Calmette-GuerinDrug
Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort A: Event Free Survival (EFS) as Assessed by the Investigator: Arm A Versus Arm CTime frame: From randomization (Day 1) to first documentation of high-grade disease, progression of disease, persistence of CIS or death due to any cause, whichever occurred first (maximum follow up duration was up to 257.1 weeks)
Locations
195 sites in 14 countries. Site status is shown where the registry gives one.
Arizona Urology Specialists
Tucson, Arizona
Arkansas Urology
Little Rock, Arkansas
Koman Family Outpatient Pavilion
La Jolla, California
Sulpizio Cardiovascular Center at UC San Diego Health
La Jolla, California
UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)
La Jolla, California
UC San Diego Moores Cancer Center
La Jolla, California
University of California Irvine Medical Center
Orange, California
UC San Diego Medical Center - Hillcrest
San Diego, California
The Urology Center of Colorado
Denver, Colorado
Urological Research Network Corp
Hialeah, Florida
UF Health Jacksonville
Jacksonville, Florida
UF Health North
Jacksonville, Florida
John H. Stroger, Jr. Hospital of Cook County
Chicago, Illinois
DuPage Medical Group
Lisle, Illinois
DuPage Medical Group Ambulatory Surgery Center
Lombard, Illinois
DuPage Medical Group
Lombard, Illinois
Edward Hospital
Naperville, Illinois
Ochsner LSU Health Shreveport - Regional Urology
Shreveport, Louisiana
Chesapeake Urology Research Associates
Hanover, Maryland
Michigan Institute of Urology, PC
Troy, Michigan
Bellevue Hospital
New York, New York
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York
NYU Langone Medical Center (Tisch Hospital)
New York, New York
NYU Langone Health Urology Associates
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Premier Medical Group of the Hudson Valley PC
Poughkeepsie, New York
Associated Medical Professionals of New York, PLLC
Syracuse, New York
Montefiore Medical Center - Montefiore Medical Park
The Bronx, New York
Montefiore Medical Center - Oncology Investigational Services
The Bronx, New York
VA Portland Healthcare System
Portland, Oregon
AUC Urologists LLC
Murrells Inlet, South Carolina
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Parkway Surgery Center
Myrtle Beach, South Carolina
Atlantic Urology Clinics South Strand Office
Myrtle Beach, South Carolina
Urology Clinics of North Texas
Dallas, Texas
Baylor University Medical Center
Dallas, Texas
Urology Clinics of North Texas
Dallas, Texas
Houston Metro Urology
Houston, Texas
Houston Methodist Hospital
Houston, Texas
Urology San Antonio PA
San Antonio, Texas
Showing 40 of 195 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.